A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model

Crit Rev Oncol Hematol. 2020 Apr:148:102896. doi: 10.1016/j.critrevonc.2020.102896. Epub 2020 Feb 8.

Abstract

Progression-free survival (PFS) hazard ratios and gain in median PFS are suggested predictors of overall survival (OS) gain (with gain defined as experimental arm minus control arm values). We assessed use of half-lives (time to progression/death of half remaining patients). We reviewed randomized trials from Journal of Clinical Oncology and New England Journal of Medicine, 01/2012-06/12/2017 (discovery series) and 01/01/2007-12/31/2011 (first validation series). If PFS or OS gains were significant, we used PFS/OS curve nonlinear regression analysis to estimate half-lives and defined "half-life gain" as experimental minus control arm half-life. With low crossover and significant PFS differences, PFS half-life gains ≥1.5 months had positive-predictive-values for OS gains ≥2 months of 79 % and 86 % and PFS half-life gains <1.5 months had negative-predictive-values for OS gains <2 months of 95 % and 75 %, in discovery and validation series, respectively. PFS half-life gains more reliably predicted OS gains than PFS hazard ratios or gains in median PFS. Findings were confirmed in a second validation series.

Keywords: Half-lives; Hazard ratios; Population kinetics; Prediction of overall survival; Progression-free survival; medians.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Disease Progression
  • Disease-Free Survival*
  • Humans
  • Medical Oncology
  • Neoplasm Recurrence, Local / mortality
  • Neoplasms / drug therapy
  • Neoplasms / mortality*
  • Neoplasms / pathology
  • Progression-Free Survival*
  • Proportional Hazards Models
  • Randomized Controlled Trials as Topic*
  • Survival Analysis

Substances

  • Antineoplastic Agents